Receptors, Antigen, T-Cell
"Receptors, Antigen, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
| Descriptor ID |
D011948
|
| MeSH Number(s) |
D12.776.543.750.705.816.824
|
| Concept/Terms |
Receptors, Antigen, T-Cell- Receptors, Antigen, T-Cell
- T-Cell Antigen Receptor
- Antigen Receptor, T-Cell
- Receptor, T-Cell Antigen
- T Cell Antigen Receptor
- T-Cell Receptors
- Receptors, T-Cell
- T Cell Receptors
- T-Cell Receptor
- Receptor, T-Cell
- T Cell Receptor
- Receptors, T-Cell Antigen
- Receptors, T Cell Antigen
- T-Cell Antigen Receptors
- Antigen Receptors, T-Cell
- Antigen Receptors, T Cell
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Antigen, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Antigen, T-Cell".
- Receptors, Antigen, T-Cell
- Complementarity Determining Regions
- Receptor-CD3 Complex, Antigen, T-Cell
- Receptors, Antigen, T-Cell, alpha-beta
- Receptors, Antigen, T-Cell, gamma-delta
This graph shows the total number of publications written about "Receptors, Antigen, T-Cell" by people in this website by year, and whether "Receptors, Antigen, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 3 | 5 |
| 1997 | 5 | 0 | 5 |
| 1998 | 4 | 3 | 7 |
| 1999 | 4 | 3 | 7 |
| 2000 | 0 | 5 | 5 |
| 2001 | 7 | 2 | 9 |
| 2002 | 3 | 3 | 6 |
| 2003 | 4 | 7 | 11 |
| 2004 | 5 | 7 | 12 |
| 2005 | 6 | 6 | 12 |
| 2006 | 5 | 4 | 9 |
| 2007 | 1 | 5 | 6 |
| 2008 | 3 | 3 | 6 |
| 2009 | 3 | 2 | 5 |
| 2010 | 4 | 2 | 6 |
| 2011 | 1 | 4 | 5 |
| 2012 | 7 | 2 | 9 |
| 2013 | 6 | 4 | 10 |
| 2014 | 7 | 3 | 10 |
| 2015 | 5 | 3 | 8 |
| 2016 | 7 | 8 | 15 |
| 2017 | 3 | 2 | 5 |
| 2018 | 10 | 5 | 15 |
| 2019 | 7 | 7 | 14 |
| 2020 | 6 | 3 | 9 |
| 2021 | 10 | 4 | 14 |
| 2022 | 1 | 15 | 16 |
| 2023 | 0 | 10 | 10 |
| 2024 | 4 | 11 | 15 |
| 2025 | 7 | 6 | 13 |
| 2026 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Antigen, T-Cell" by people in Profiles.
-
Peripheral vision: Treg cell induction in the gut. Immunity. 2026 Aug 11; 59(8):2061-2063.
-
Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Blood. 2026 08 06; 148(6):657-668.
-
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
-
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. J Immunother Cancer. 2026 Jul 20; 14(7).
-
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. Cancer Res Commun. 2026 07 01; 6(7):1681-1692.
-
Mapping the TCR landscape: computational tools empowering translational immunology and therapy design. J Immunother Cancer. 2026 Jun 18; 14(6).
-
APOL1 risk alleles modulate T cell receptor signaling to promote allograft rejection. J Clin Invest. 2026 Aug 03; 136(15).
-
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica. 2026 06 01; 111(6):1999-2010.
-
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma. J Clin Oncol. 2026 01 10; 44(2):86-91.
-
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL. Blood Adv. 2025 Sep 09; 9(17):4405-4414.